医疗ETF（159828）飘红，连续3日迎资金净流入，中国创新药竞争力凸显

Group 1 - The core viewpoint of the article highlights the positive signals from the JPM conference, reinforcing the industrial positioning of AI in healthcare [1] - In early 2026, multiple AI pharmaceutical collaborations have been established globally, with over 9 partnerships among multinational pharmaceutical companies, totaling more than $6 billion [1] - AI in pharmaceuticals enhances the entire drug development process, improving efficiency and success rates in new drug discovery, preclinical screening, clinical development, and production, indicating a future high-growth trajectory [1] Group 2 - Continuous attention should be paid to investment directions in AI healthcare, including AI health management, AI medical information technology, AI medical imaging, AI surgical robots, AI gene sequencing, and AI pharmaceuticals [1] - The competitiveness of Chinese innovative pharmaceuticals is highlighted, with Chinese companies actively engaging in business development overseas in areas such as bispecific antibodies, ADCs, and GLP-1RA new drugs by 2025 [1] - The medical ETF (159828) tracks the CSI Medical Index (399989), which selects listed companies in the A-share market involved in medical devices, medical services, and medical information technology, reflecting the overall performance of healthcare-themed listed companies [1]